Sucampo Pharma, Ltd., Announces Start Of Phase 2b Study In Japan To Evaluate Lubiprostone For Chronic Idiopathic Constipation
Dec 6th 2007Drug InformationGastroIntestinal / Gastroentorology
Sucampo Pharma Ltd. (SPL), a wholly-owned Japanese subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a specialty pharmaceutical company developing prostone-based therapies for age-related and other diseases, announced the initiation of a multi-center Phase 2b dose-ranging study in Japan to evaluate the safety and efficacy of lubiprostone for adult Chronic Idiopathic Constipation. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
